Tumor Paint BLZ-100

The Newro Foundation is currently enrolling patients in a clinical study of Tumor Paint BLZ-100, an investigational intra-operative imaging agent for cancer. Tumor Paint, BLZ-100 is being developed by Blaze Bioscience, the Tumor Paint Company® in Seattle, Washington, U.S. The study is actively recruiting adult patients with glioma undergoing surgery at the Newro Foundation under the direction of Dr. David Walker.  The study is also being conducted at Cedars-Sinai Medical Center in Los Angeles.

BLZ-100 in an intra-operative fluorescent imaging agent and consists of an Optide (optimized peptide), which binds and internalizes into cancer cells, and a fluorescent dye which emits light in the near-infrared range. BLZ-100 is designed to provide real-time, high-resolution intraoperative visualization of cancer cells, enabling more precise, complete resection of cancer throughout surgery.

BLZ-100 is currently in multiple Phase 1 proof-of-concept clinical studies to evaluate the safety and imaging characteristics of BLZ-100 in several different types of cancer, including brain cancer.  

Watch this video from Blaze for more information about this trial.

 

Further information:

Clinical Trial - Newro Foundation Research Nurse on 07 3833 2500 or email info@newrofoundation.com.au

Media enquiries - Thy Boskovic on 0421 483 174 or email info@newrofoundation.com.au